Zsa Zsa Weerts

Cost-effectiveness of peppermint oil in IBS 205 8 evaluation conducted alongside a pragmatic randomised controlled trial in primary care. BMC Gastroenterol 2012;12:149. 26. Sampaio F, Bonnert M, Olen O, et al. Cost- effectiveness of internet-delivered cognitive- behavioural therapy for adolescents with irritable bowel syndrome. BMJ Open 2019;9:e023881. 27. Shah ED, Salwen-Deremer JK, Gibson PR, et al. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. Clin Gastroenterol Hepatol 2020;DOI 10.1016/j.cgh.2020.09.043. 28. Rao S, Lembo A, Shiff S, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation, The American journal of gastroenterology. 2012, 107 , 1714-1724; quiz p 1725. 29. Brenner D, Fogel R, Dorn S, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials, The American journal of gastroenterology. 2018, 113 , 735- 745. 30. Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo- Controlled Phase 3 Trial (T3MPO-1), The American journal of gastroenterology. 2020, 115 , 281-293. 31. Shah E, Eswaran S, Chey W. How Cost- Effectiveness Impacts Treatment Choice in Irritable Bowel Syndrome: A Cost- Effectiveness Analysis of Guideline Recommended Over-the-Counter Treatments and Low FODMAP Diet From a Patient Perspective: 1132. Am J Gastroenterol 2017;112. 32. European Pharmacopoeia Commission. European Pharmacopoeia (Ph.Eur.) Monograph Peppermint oil., 2014. 33. European Medicines Agency (EMA). Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CHMP/60337. 2013. 34. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry - Clinical Evaluation of Drugs for Treatment. 2012. 35. de Vroome E, de Koppes L, Smulders P, et al. Verzuimmeting via zelfrapportage en registratie: verschillen tussen de Nationale Enquête Arbeidsomstandigheden en de Nationale Verzuim Statistiek. TSG 2010; 88:71-78. 36. Patel A, Rendu A, Moran P, et al. A comparison of two methods of collecting economic data in primary care. Fam Pract 2005;22:323-327.